Mizuho Maintains Outperform on Biogen, Lowers Price Target to $251
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed maintains an Outperform rating on Biogen (NASDAQ:BIIB) but lowers the price target from $277 to $251.
August 06, 2024 | 11:19 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mizuho analyst Salim Syed maintains an Outperform rating on Biogen but lowers the price target from $277 to $251.
The Outperform rating suggests continued confidence in Biogen's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100